The yin and yang of B cells in graft rejection and tolerance (Q37690953)

22 August 2017

1 reference

title

The yin and yang of B cells in graft rejection and tolerance (English)

1 reference

22 August 2017

Valeriya Zarkhin

1

1 reference

22 August 2017

Geetha Chalasani

series ordinal

2

1 reference

22 August 2017

Minnie M Sarwal

series ordinal

3

1 reference

22 August 2017

publication date

10 February 2010

1 reference

22 August 2017

published in

Transplantation Reviews

1 reference

22 August 2017

volume

24

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

67-78

1 reference

Banff 07 classification of renal allograft pathology: updates and future directions

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

CD20 lymphocytes in renal allografts are associated with poor graft survival in pediatric patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Association of CD20 infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Humoral theory of transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Biopsy eosinophilia as a predictor of renal graft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

The changing role of natural killer cells in solid organ rejection and tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Kidney and pancreas transplantation in the United States, 1996-2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Characterization of intra-graft B cells during renal allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

"To B or not to B?" B-cells and graft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Dense B cell infiltrates in paediatric renal transplant biopsies are predictive of allograft loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

T-cell-B-cell cooperation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Two levels of help for B cell alloantibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

The specific direct interaction of helper T cells and antigen-presenting B cells. II. Reorientation of the microtubule organizing center and reorganization of the membrane-associated cytoskeleton inside the bound helper T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

The CD40-CD154 interaction in B cell-T cell liaisons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Deficient CD4 T cell priming and regression of CD8 T cell functionality in virus-infected mice lacking a normal B cell compartment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Investigation of the role of B-cells in type 1 diabetes in the NOD mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Cutting edge: B cells promote CD8 T cell activation in MRL-Fas(lpr) mice independently of MHC class I antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Reciprocal regulation of polarized cytokine production by effector B and T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Primed peritoneal B lymphocytes are sufficient to transfer protection against Brugia pahangi infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Neonatal B cells suppress innate toll-like receptor immune responses and modulate alloimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

TNF/TNFR family members in costimulation of T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Lymphoid neogenesis in rheumatoid synovitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Tertiary lymphoid tissues generate effector and memory T cells that lead to allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

A role for antibodies in the generation of memory antifungal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Immune complex-mediated antigen presentation induces tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

How antibodies act as natural adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Modulation of dendritic cell maturation and function by B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8 CTL responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Antibody-induced transplantation tolerance that is dependent on thymus-derived regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

[Novel B-cell directed strategies for the treatment of rheumatic diseases]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Deciphering antibody-mediated rejection: new insights into mechanisms and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Control of anti-donor antibody production post-transplantation: conventional and novel immunosuppressive therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Reducing antibody levels in patients undergoing transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Rituximab as treatment for refractory kidney transplant rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Pharmacodynamics of Rituximab in Kidney Allotransplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Rituximab therapy for acute humoral rejection after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Successful third kidney transplantation with intensive immunosuppression in a highly sensitized recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Impact of rituximab therapy for treatment of acute humoral rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Regulated expression of BAFF-binding receptors during human B cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

BAFF: a fundamental survival factor for B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

BAFF AND APRIL: a tutorial on B cell survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

B cell-targeted therapy for rheumatoid arthritis: an update on the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Reconstitution of peripheral allospecific CD19 B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Rituximab and intravenous immune globulin for desensitization during renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Management of highly sensitized patients: capitol medical center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

B-cell-depleting induction therapy and acute cellular rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Differential expression of profibrotic and growth factors in chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Expression of surfactant protein-C, S100A8, S100A9, and B cell markers in renal allografts: investigation of the prognostic value.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Arraying the orchestration of allograft pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Expression profiling on chronically rejected transplant kidneys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Proteasome inhibition reduces donor-specific antibody levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Abrogation of anti-HLA antibodies via proteasome inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

Proteasome inhibition for antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRRE.2010.01.004

10.1016/J.TRRE.2010.01.004

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference